Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Set To Green-Light First mRNA Vaccine

Domestic Contender A First Step Out Of 'COVID Zero'?

Executive Summary

In what appears to be a step towards a gradual shift away from its strict "COVID Zero" policies, China is poised to approve its first mRNA vaccine - in this case developed domestically - and will accelerate the roll-out of COVID-19 vaccinations in general to seniors over 80.

You may also be interested in...



Drugs In Short Supply As China Hunkers Down For COVID Surge

As citizens in China grapple with the virtual end of pandemic restrictions and rush for medicines from cold remedies to traditional options, even some prescription antivirals such as Paxlovid are appearing online, while cheaper but unauthorized Indian generic versions have quickly sold out. Meanwhile, a renewed vaccination effort is targeting high-risk individuals and second booster shots as the country faces a huge surge in cases.

Scholz Visit Paves Way For Limited China BioNTech Vaccine Use

Recent visits by foreign dignitaries and progress with local mRNA vaccines and antivirals appear to be helping some slight relaxations in China's strict COVID policies, but some experts predict it may still take months for further steps.

Behind A Rekindled Dream And China Biotech’s New Reality

The latest mega deals aimed at bringing Chinese innovation to the US have rekindled go-global hopes for a sector badly needing some cheer. But some investors say out-licensing may be the best route and that Chinese biotech must scale back its do-all mentality and focus on what it does best amid a new reality.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel